ESR1 and breast carcinoma: In support of this notion, efficacy of pembrolizumab was observed in 28% of patients with ER+ breast cancer.19,20 Measurement of cancer cell levels of PD-L2 in ER+ breast tumors likely will be informative for response to PD-1 inhibitors or yet to be developed PD-L2 inhibitors.